Argatroban therapy does not generate antibodies that alter its anticoagulant activity in patients with heparin-induced thrombocytopenia

Thrombosis Research

Volumn 105, Issue 5, 2002, Pages 401-405

  Walenga, Jeanine M ^a   Ahmad, Sarfraz ^a   Hoppensteadt, Debra ^a   Iqbal, Omer ^a   Hursting, Marcie J ^b   Lewis, Bruce E ^a  

^a LOYOLA UNIVERSITY MEDICAL CENTER   (United States)

^b Clinical Science Consulting   (United States)

Author keywords

Antibodies; Argatroban; Heparin induced thrombocytopenia; Hirudin; Immunogenicity

Indexed keywords

ARGATROBAN; DRUG ANTIBODY; HEPARIN; IMMUNOGLOBULIN G; LEPIRUDIN; THROMBIN INHIBITOR; ANTIBODY; ANTICOAGULANT AGENT; PIPECOLIC ACID DERIVATIVE;

ANTIBODY ISOLATION; ANTIBODY PRODUCTION; ANTICOAGULATION; BLOOD SAMPLING; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DILATATION; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG REEXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HUMAN; IMMUNOGENICITY; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; THROMBOCYTOPENIA; THROMBOSIS PREVENTION; ARTICLE; BLOOD; CHEMICALLY INDUCED DISORDER; IMMUNOLOGY; THROMBOSIS;

ANTIBODIES; ANTICOAGULANTS; DOSE-RESPONSE RELATIONSHIP, DRUG; HEPARIN; HUMANS; PARTIAL THROMBOPLASTIN TIME; PIPECOLIC ACIDS; THROMBOCYTOPENIA; THROMBOSIS;

EID: 0036507937     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0049-3848(02)00049-X     Document Type: Conference Paper

References (24)

1. A 14-year study of heparin-induced thrombocytopenia
2. Failure of early heparin cessation as treatment for heparin-induced thrombocytopenia
3. Heparin-induced thrombocytopenia
4. Argatroban anticoagulant therapy in patients with heparin-induced thrombocytopenia
5. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
6. Antihirudin antibodies in patients with heparin-induced thrombocytopenia treated with lepirudin: Incidence, effects on aPTT, and clinical relevance
7. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
8. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment
9. Re-exposure to recombinant (r)-hirudin in antihirudin antibody-positive patients with a history of heparin-induced thrombocytopenia
10. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
11. Comparison of anticoagulant effects and safety of argatroban and heparin in healthy subjects
12. A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: Myocardial Infarction with Novastan and TPA (MINT) trial
13. Argatroban and alteplase in patients with acute myocardial infarction: The ARGAMI study
14. Evidence for a rebound coagulation phenomenon after cessation of a 4-hour infusion of a specific thrombin inhibitor in patients with unstable angina pectoris
15. Argatroban during percutaneous transluminal coronary angioplasty: Results of a dose-verification study
16. Effect of thrombin inhibition on patients with peripheral arterial obstructive disease: A multicenter clinical trial of argatroban
17. Effect of the thrombin inhibitor argatroban in acute cerebral thrombosis
18. Successful coronary interventions performed with argatroban anticoagulation in patients with heparin-induced thrombocytopenia and thrombosis syndrome
19. Argatroban reexposure in patients with heparin-induced thrombocytopenia (abstract)
20. Argatroban anticoagulation during initial and repeat percutaneous coronary intervention in patients with heparin-induced thrombocytopenia (abstract)
21. Newer avenues in the monitoring of antithrombotic therapy: The role of automation
22. Purification of IgG from serum with caprylic acid and ammonium sulphate precipitation is not superior to ammonium sulphate precipitation alone
23. Functional heterogeneity of antiheparin-platelet factor 4 antibodies: Implications in the pathogenesis of the HIT syndrome
24. Practical guidance for incremental dosage adjustment during argatroban anticoagulation in patients with heparin-induced thrombocytopenia